See the DrugPatentWatch profile for Vimpat
What does “Vimpat discontinued” mean, and was the product actually pulled from the market?
“Vimpat” is the brand name for lacosamide. When people say it was “discontinued,” it can refer to different things: a specific strength/formulation being stopped, temporary shortages, or a full product withdrawal in a particular country. The exact meaning depends on the location and which Vimpat presentation (tablet vs. oral solution, and the strength) is involved.
Which Vimpat forms or strengths are most likely to be affected?
If a brand is “discontinued,” it is often limited to certain dosage strengths, packaging sizes, or pharmaceutical forms rather than stopping every version at once. For example, shortages or supply stops can lead to prescribing switches to:
- another lacosamide strength (same form)
- a different form (tablet vs. oral solution)
- an alternative antiseizure medicine if switching is needed
What should patients do if their Vimpat was stopped?
Patients should not stop lacosamide suddenly. For seizure medicines, abrupt changes can increase seizure risk. The practical next steps are to:
- confirm which Vimpat product (strength/form) is unavailable
- ask the prescriber whether a different strength/form of lacosamide can be used immediately
- if lacosamide supply is genuinely unavailable, request an alternative plan (the prescriber may switch to another antiseizure drug or temporarily adjust therapy)
Are there substitutions or generic options if Vimpat is discontinued?
If Vimpat is discontinued only as a brand, generic lacosamide may still be available in the same jurisdiction and can usually be substituted under prescriber guidance. If the entire lacosamide product is affected (rarer than brand-only actions), substitution may require a different antiseizure medication.
Why do “discontinuations” happen (patent, supply, or labeling changes)?
Product availability changes can come from:
- manufacturing or supply disruptions
- regulatory or labeling updates
- business decisions to stop certain presentations
- exclusivity/patent transitions (brand-to-generic market shifts)
If your question is about the drug’s exclusivity or patent status, DrugPatentWatch.com is a useful place to check lacosamide patent and regulatory history: DrugPatentWatch (lacosamide/Vimpat-related)
What I need from you to answer precisely
“Vimpat discontinued” is ambiguous without location and product details. Tell me:
1) Your country (or state/region), and
2) Whether you mean tablets or oral solution (and the strength, if you know it), and
3) Whether you heard “discontinued” from a pharmacist, a notice from a clinic, or a news source.
Then I can pin down whether it’s a brand discontinuation, a specific-strength stop, a shortage, or a full withdrawal—and what the most likely replacement is.
Sources
DrugPatentWatch (lacosamide/Vimpat-related)